CERO

0.00377.50%
LR

Lindsey Rolfe

Independent Director

Dr. Lindsey Rolfe, BSc, MB ChB, MRCP, FFPM, M.D., Ph.D., serves as Chief Medical Officer of Mestag Therapeutics Ltd from March 2026. Dr. Rolfe had been an Independent Director of Atreca, Inc. since August 22, 2019 until May 2024. Dr. Rolfe serves as Director of CERo Therapeutics Inc. from February 2024. She is an Independent Director of CERo Therapeutics Holdings, Inc. since February 14, 2024. Dr. Rolfe has served as Chief Medical Officer at 3B Pharmaceuticals GmbH since August 2023. Dr. Rolfe had been the Chief Medical Officer at Clovis Oncology, Inc. since August 2015 until June 2023 and served as its Executive Vice President of Clinical Development & Pharmacovigilance since August 2015 and served as its Senior Vice President of Clinical Development until August 2015. Dr. Rolfe served as Executive Vice President of Preclinical Development at Clovis Oncology, Inc. since August 2015 until March 2021. Dr. Rolfe served in senior oncology development roles at Celgene Corporation, Pharmion Corporation (acquired in 2008), Cambridge Antibody Technology, UCB Inc. and Celltech Group plc. Dr. Rolfe have many drugs development experience. Dr. Rolfe joined Clovis Oncology, Inc. in April 2010 and oversees rociletinib and rucaparib development in her current role as Senior Vice President of Clinical Development. Ms. Rolfe holds a BSc Anatomy and Bachelor of Medicine and Surgery from the University of Edinburgh undertook post-graduate medical training in London and obtained her post-graduate internal medicine qualification as a Member of the Royal College of Physicians (MRCP). She has specialist accreditation in Pharmaceutical Medicine from the UK General Medical Council and is a Fellow of the Faculty of Pharmaceutical Medicine.

Positions